To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma
Read time: Less than a minute
SeqWright Inc., a CLIA certified and GLP compliant provider of custom genomic and molecular biology services, announced its entry into the genetically-targeted therapy field through its partnership with PharmaGenoma.
SeqWright will be the exclusive genetic testing provider for PharmaGenoma's HairDX test which evaluates patient responsiveness to the common hair loss treatment, Finasteride.
Finasteride is a commonly prescribed medication for the treatment of Androgenic Alopecia (AGA) or common hair loss. The treatment works by blocking the production of dihydrotesterone (DHT), which is responsible for the loss of hair.
However, due to potential Finasteride side effects, along with variations in responsiveness, many patients are reluctant to begin or continue treatment. In order to overcome this obstacle, HairDX developed a genetic test for Finasteride response which will allow patients to determine if treatment benefits outweigh potential side effects prior to beginning a Finasteride regimen.
"The state of the art research facility at SeqWright was essential to achieving our goals of high quality genetic analysis combined with a turn-around time useful for clinicians," said PharmaGenoma, CEO Andy Goren.
SeqWright will be the exclusive genetic testing provider for PharmaGenoma's HairDX test which evaluates patient responsiveness to the common hair loss treatment, Finasteride.
Finasteride is a commonly prescribed medication for the treatment of Androgenic Alopecia (AGA) or common hair loss. The treatment works by blocking the production of dihydrotesterone (DHT), which is responsible for the loss of hair.
However, due to potential Finasteride side effects, along with variations in responsiveness, many patients are reluctant to begin or continue treatment. In order to overcome this obstacle, HairDX developed a genetic test for Finasteride response which will allow patients to determine if treatment benefits outweigh potential side effects prior to beginning a Finasteride regimen.
"The state of the art research facility at SeqWright was essential to achieving our goals of high quality genetic analysis combined with a turn-around time useful for clinicians," said PharmaGenoma, CEO Andy Goren.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
